Drug repositioning specialist Biovista Inc. has tapped Hewlett Packard Enterprise Co. (HPE) to add greater computing power to Project Prodigy, a personalized medicine platform that leverages artificial intelligence (AI) to help doctors identify novel drugs for hard-to-treat patients. HPE, a spin-off of HP Inc. focused on data analysis and security, is also providing financial and commercial support to help Biovista explore new applications for the system beyond health care, president and co-founder Aris Persidis told BioWorld.